Kaitlyn D’Onofrio

DocwireNews

Many unknowns remain about COVID-19, with researchers working to discover good information. One area of exploration is how different medications may affect patients who contract COVID-19, particularly immunosuppressed patients. Recently, researchers examined outcomes associated with COVID-19 among patients with underlying <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/heres-how-rheumatic-patients-were-affected-during-the-early-days-of-the-covid-19-pandemic/">rheumatic diseases</a> taking immunosuppressive agents.&ldquo;In the medical community, Rheumatologists are particularly concerned because their patients represent a population of autoimmune rheumatic disorders who are mostly on immunosuppressive agents and are susceptible to infection. While much has been learnt on COVID-19 in general, little is known of COVID-19 severity and outcomes in patients with rheumatic diseases (RD),&rdquo; explained the study authors.The present study was a retrospective chart review of COVID-19 patients with rheumatic diseases who were taking <a href="https://www.docwirenews.com/abstracts/rheumatology-abstracts/a-comparative-study-of-fibromyalgia-rheumatoid-arthritis-spondyloarthritis-and-sjogrens-syndrome-impact-of-the-disease-on-quality-of-life-psychological-adjustment-and-use-of-coping-strategies/">disease-modifying antirheumatic drugs (DMARDs)</a>. The researchers also performed a literature search and assessed similar studies of single cases and case series.The retrospective chart review included four COVID-19 inpatients with rheumatic diseases (mean age, 57 years). Half of the patients had a mild infection, and the other half progressed to severe disease and presented respiratory complications; one severe case on secukinumab required mechanical ventilation, and the other on rituximab developed viral pneumonia and needed supplemental oxygenation. Elevated acute phase reactants wee observed in all four patients; two patients with mild COVID-19 presented lymphopenia, and two patients with severe COVID-19 had normal lymphocyte counts and elevated IL-6 levels. No patients experienced exacerbations of their underlying rheumatic diseases.The literature review yielded nine relevant COVID-19 studies encompassing 197 cases of patients with inflammatory rheumatic diseases. The majority of patients were taking DMARDs or biologics, the most commonly used being anti-tumor necrosis factor (TNF) inhibitors. Two patients taking tocilizumab had a mild infection. Two patients were taking rituximab, one of whom had severe infection and required mechanical ventilation. Six patients were taking secukinumab, one of whom was hospitalized.Twelve patients died, for an estimated overall mortality rate for the 201 cases&mdash;the four from the researchers&rsquo; hospital and the 197 identified in the literature review&mdash;of 5.9%.The study will appear in the August issue of <a href="https://www.sciencedirect.com/science/article/pii/S0049017220301438?via%3Dihub">Seminars in Arthritis and Rheumatism</a>.The study authors concluded that, &ldquo;RD patients are susceptible to COVID-19. Various DMARDs may affect the viral process differently. Patients on etanercept, [hydroxychloroquine], or tocilizumab may run a mild course of the viral illness. Rituximab or secukinumab could worsen the viral disease and its related complications.&rdquo; They called for larger studies in the future.

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

What Does COVID-19 Look Like in Patients Taking Immunosuppressive Agents?

COVID-19

Many unknowns remain about COVID-19, with researchers working to discover good information. One area of exploration is how different medications may affect patients who ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe